Twice-weekly treatment with tacrolimus 0.03% ointment in children with atopic dermatitis: Clinical efficacy and economic impact over 12 months

Journal of the European Academy of Dermatology and Venereology

Volumn 24, Issue 9, 2010, Pages 1040-1046

  Thaci, D ^a   Chambers, C ^b   Sidhu, M ^b   Dorsch, B ^c   Ehlken, B ^d   Fuchs, S ^d  

^a GOETHE UNIVERSITY   (Germany)

^b ASTELLAS PHARMA EUROPE LTD   (United Kingdom)

^c Metronomia GmbH   (Germany)

^d IQVIA   (United States)

Author keywords

atopic dermatitis; children; cost analysis; tacrolimus ointment

Indexed keywords

TACROLIMUS;

ADOLESCENT; ARTICLE; ATOPIC DERMATITIS; CAREGIVER; CHILD; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OINTMENT; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; STRUCTURED QUESTIONNAIRE; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADOLESCENT; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OINTMENTS; TACROLIMUS; TREATMENT OUTCOME;

EID: 77955249764     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03577.x     Document Type: Article

References (38)

1. Akdis CA, Akdis M, Bieber T et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy 2006 61 : 969 987. (Pubitemid 44024897)
2. Ring J, Wenning J. Weißbuch Allergie in Deutschland 2000, Deutsche Gesllschaft fütr Allergologie und Immunologie (DGAI). Urban&Vogel Medien und medizin Verlagsgesellschaft mbH&Co.Kg, Munich, 2000.
3. Schafer T, Vieluf D, Behrendt H et al. Atopic eczema and other manifestations of atopy: results of a study in East and West Germany. Allergy 1996 51 : 532 539.
4. Weiland SK, von ME, Hirsch T et al. Prevalence of respiratory and atopic disorders among children in the East and West of Germany five years after unification. Eur Respir J 1999 14 : 862 870.
5. Ehlken B, Mohrenschlager M, Kugland B et al. [Cost-of-illness study in patients suffering from atopic eczema in Germany]. Hautarzt 2005 56 : 1144 1151.
6. Kissling S, Wuthrich B. [Follow-up of atopic dermatitis after early childhood]. Hautarzt 1993 44 : 569 573.
7. Statistisches Bundesamt. Spezialbericht Allergien. Metzler Poeschel Verlag, Stuttgart, 2000.
8. Emerson RM, Williams HC, Allen BR. Severity distribution of atopic dermatitis in the community and its relationship to secondary referral. Br J Dermatol 1998 139 : 73 76.
9. Bieber T. Atopic dermatitis. N Engl J Med 2008 358 : 1483 1494.
10. Fischer S, Ring J, Abeck D. [Atopic eczema: spectrum of provocation factors and possibilities for their effective reduction and elimination]. Hautarzt 2003 54 : 914 924.
11. Carroll CL, Balkrishnan R, Feldman SR et al. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol 2005 22 : 192 199.
12. Augustin M, Zschocke I, Lange S et al. [Quality of life in skin diseases: methodological and practical comparison of different quality of life questionnaires in psoriasis and atopic dermatitis]. Hautarzt 1999 50 : 715 722.
13. Augustin M, Zschocke I. Lebensqualität und Ökonomie bei allergischen Hauterkrankungen. Allergologie 2001 2001 : 433 442.
14. Gieler U, Hohmann M, Niemeier V et al. Cost evaluation in atopic eczema. J Dermatolog Treat 1999 10 (Suppl. 1 15 21.
15. Abeck D, Strom K. Optimal management of atopic dermatitis. Am J Clin Dermatol 2000 1 : 41 46.
16. Darsow U, Lubbe J, Taieb A et al. Position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2005 19 : 286 295.
17. Hague J, Berth-Jones J. Current management of atopic eczema in primary care. Prescriber 2005 16 : 50 57.
18. Morris AD. Effects of long-term topical corticosteroids. Dermatol Pract 1998 6 : 5 8.
19. Barbeau M, Bpharm HL. Burden of atopic dermatitis in Canada. Int J Dermatol 2006 45 : 31 36.
20. Zuberbier T, Orlow SJ, Paller AS et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 2006 118 : 226 232.
21. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000 142 : 931 936.
22. Alomar A, Berth-Jones J, Bos JD et al. The role of topical calcineurin inhibitors in atopic dermatitis. Br J Dermatol 2004 151 (Suppl. 70 3 27. (Pubitemid 40023628)
23. Paller A, Eichenfield LF, Leung DY et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001 44 : S47 S57.
24. Reitamo S, Van Leent EJ, Ho V et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002 109 : 539 546. (Pubitemid 34234208)
25. Reitamo S, Harper J, Bos JD et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol 2004 150 : 554 562.
26. Remitz A, Harper J, Rustin M et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. Acta Derm Venereol 2007 87 : 54 61. (Pubitemid 46225392)
27. Thaçi D, Reitamo S, Gonzalez Ensenat MA et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol 2008 159 : 1348 1356.
28. Hanifin J. EASI correlates with IGA and validates its use as a measure of atopic eczema. Presented at the 61st Annual Meeting of the American Academy of Dermatology, 21-26 March 2003, San Francisco, CA, USA [Abstr. P210].
29. Editio Cantor Verlag. Rote Liste 2005. Cantor Verlag, Aulendorf, 2005.
30. Einheitlicher Bewertungsmaßstab. [German tarif list for drugs in Germany EBM 2000plus]. Kassenärtzliche Bundesvereinigung. [WWW document] 2008. URL http://www.ebm2000plus.de (last accessed: 16 June 2009).
31. Fallpauschalenkatalog. Institut für das Entgeldsystem im Krankenhaus. [WWW document] DRG-System, 2006. URL http://www.g-drg.de (last accessed: 16 June 2009).
32. Bundesministerium für Gesundheit u.Soz. SI: Bestimmung Landes-Basisfallwerte im Fallpaulschaschschalsystem füt Krankenhäuser 2006. Bundesministerium für Gesundheit, Berlin, 2007.
33. Statistisches Bundesamt. Statistisches Jahrbuch 2005 für die Bundesrepublik Deutschland. Metzler-Poeschel, Wiesbaden, 2005.
34. Thaci D. Efficacy of twice-weekly tacrolimus 0.03% ointment for children with mod+severe atopic dermatitis. Presented at the 10th International Congress of Dermatology, Prague, Czech Republic, May 20-24, 2009.
35. Rathjen D, Thiele K, Staab D et al. Die geschätzten Kosten von Neurodermitis bei Kindern. Z Gesundheitswissenschaften 2000 8 : 25.
36. Weinmann S, Kamtsiuris P, Henke KD et al. The costs of atopy and asthma in children: assessment of direct costs and their determinants in a birth cohort. Pediatr Allergy Immunol 2003 14 : 18 26.
37. Garside R, Stein K, Castelnuovo E et al. The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a systematic review and economic evaluation. Health Technol Assess 2005 9 : iii, xi-iii, 230.
38. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for Economic Evaluation of Health Care Programmes, 2nd edn. Oxford University Press, Oxford, 1997.